Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O'Connor will assume the role of Chief Executive Officer on December 1, 2026, succeeding Andreas Pecher, who has served as interim CEO since January 1, 2026. The appointment, first announced in May 2026, was reported by NEWMEDIAWIRE.
O'Connor joins from Vitrolife Group in Sweden, where she has been CEO since 2023. She will also join the Executive Board of Carl Zeiss AG, taking responsibility for the Medical Technology segment. Her career spans leadership roles at Johnson & Johnson, Covidien (later acquired by Medtronic), and Thermo Fisher Scientific, where she served as Global President of the Immunodiagnostics Division.
"I am delighted to join Carl Zeiss Meditec and the ZEISS Group," O'Connor said. "The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company's transformation."
Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, said: "With Bronwyn Brophy O'Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company." Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG, thanked Pecher for his interim leadership and added that O'Connor "will now be able to further advance the strategy and transformation of the Medical Technology segment."
The leadership change comes as Carl Zeiss Meditec, a leading medical technology company with 5,784 employees and revenue of EUR 2,228 million in fiscal year 2024/25, seeks to accelerate innovation in eye disease diagnosis and treatment and microsurgery visualization. O'Connor's extensive international experience, including roles in Ireland, Spain, the U.K., Switzerland, Sweden, and the U.S., is expected to bolster the company's global reach and customer focus.
Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise O'Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will include Andreas Pecher as President and CEO, Stefan Müller as CFO, O'Connor as Head of the Medical Technology segment, Sven Hermann as Head of Consumer Markets, Dr. Frank Rohmund as Head of Semiconductor Manufacturing Technology, and Dr. Marc Wawerla as Head of Industrial Quality & Research.
For investors and industry observers, the appointment signals continuity in strategy and a strengthened focus on customer-driven innovation. O'Connor's track record in business transformation and her deep medtech background position her to steer Carl Zeiss Meditec through its next phase of growth. More information is available at www.zeiss.com/newsroom.
